LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Exclusion Criteria

• •1. Secondary hypertrophic cardiomyopathy (aortic stenosis, hypertension, amyloidosis and all phenocopies…)
• •2. Signs of heart failure
• •3. Hospitalization
• •4. Uncontrolled blood pressure
• •5. Creatinine clearance \<30 mL/min (Cockcroft)
• •6. Severe liver dysfunction, cirrhosis Child B or C
• •7. Any anticoagulation therapy in the 15 days prior to enrollment
• •8. Any cardiac surgery in the 30 days prior to enrollment
• •9. Documented atrial arrhythmia
• •10. Any major bleeding in the 90 days prior to enrollment
• •11. Need to be on dual antiplatelet therapy (aspirin \>100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel…).
• •12. Contraindication for a brain magnetic resonance imaging exam
• •13. Known hypersensitivity or others contraindications to Rivaroxaban (refer to contraindications)
• •14. Ischemic stroke or intracranial hemorrhage in the 30 days prior to enrollment
• •15. Active endocarditis at the time of enrollment
• •16. Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors
• •17. Active cancer or life expectancy less than 3 years
• •18. Non-compliant
• •19. Participation in another interventional clinical trial
• •20. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman or planning pregnancy during the study period and minor)
• •21. Absence of coverage by a social security scheme